|
GB0115256D0
(en)
|
2001-06-21 |
2001-08-15 |
Babraham Inst |
Mouse light chain locus
|
|
WO2003034903A2
(en)
|
2001-10-23 |
2003-05-01 |
Psma Development Company, L.L.C. |
Psma antibodies and protein multimers
|
|
GB2398784B
(en)
|
2003-02-26 |
2005-07-27 |
Babraham Inst |
Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
|
|
GB0400440D0
(en)
|
2004-01-09 |
2004-02-11 |
Isis Innovation |
Receptor modulators
|
|
ES2386366T3
(es)
|
2005-02-18 |
2012-08-17 |
Medarex, Inc. |
Anticuerpo monoclonal humano contra el antígeno de membrana específico de la próstata (PSMA)
|
|
EP1919504B1
(en)
|
2005-08-03 |
2013-10-16 |
iBio, Inc. |
Antibody to bacillus anthracis protective antigen
|
|
US8168757B2
(en)
|
2008-03-12 |
2012-05-01 |
Merck Sharp & Dohme Corp. |
PD-1 binding proteins
|
|
JP2011514385A
(ja)
|
2008-03-17 |
2011-05-06 |
アラーガン、インコーポレイテッド |
炎症を処置するためのｓ１ｐ３受容体阻害剤
|
|
US20100122358A1
(en)
|
2008-06-06 |
2010-05-13 |
Crescendo Biologics Limited |
H-Chain-only antibodies
|
|
WO2010036959A2
(en)
|
2008-09-26 |
2010-04-01 |
Dana-Farber Cancer Institute |
Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
|
|
US20130202623A1
(en)
|
2010-02-16 |
2013-08-08 |
Nicolas Chomont |
Pd-1 modulation and uses thereof for modulating hiv replication
|
|
TW201134488A
(en)
|
2010-03-11 |
2011-10-16 |
Ucb Pharma Sa |
PD-1 antibodies
|
|
US20130266567A1
(en)
|
2010-12-01 |
2013-10-10 |
Haren Arulanantham |
Anti-serum albumin binding single variable domains
|
|
CA3285826A1
(en)
|
2012-02-22 |
2026-03-02 |
The Trustees Of The University Of Pennsylvania |
Compositions and methods for generating a persisting population of t cells useful for the treatment of cancer
|
|
WO2013167883A1
(en)
|
2012-05-07 |
2013-11-14 |
The University Court Of The University Of Aberdeen |
Single domain binding molecule
|
|
CN103087171B
(zh)
|
2012-12-24 |
2015-01-14 |
中国人民解放军第四军医大学 |
一种用于前列腺癌早期诊断和治疗的抗psma/fitc双特异性抗体及其制备方法
|
|
US10993420B2
(en)
|
2013-03-15 |
2021-05-04 |
Erasmus University Medical Center |
Production of heavy chain only antibodies in transgenic mammals
|
|
CN103333249A
(zh)
|
2013-06-14 |
2013-10-02 |
广州康合生物科技有限公司 |
一种抗前列腺特异性膜抗原（psma）的单克隆抗体及其应用
|
|
MX2016002544A
(es)
|
2013-09-04 |
2016-06-17 |
Squibb Bristol Myers Co |
Compuestos utiles como inmunomoduladores.
|
|
TWI681969B
(zh)
*
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對ｐｄ-１的人類抗體
|
|
TWI680138B
(zh)
*
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗ｐｄ-ｌ１之人類抗體
|
|
UA122479C2
(uk)
|
2014-01-24 |
2020-11-25 |
Дана-Фарбер Кенсер Інстітьют, Інк. |
Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
|
|
KR20150089702A
(ko)
|
2014-01-28 |
2015-08-05 |
제일모직주식회사 |
신규 화합물, 신규 폴리머, 이를 포함하는 착색제, 이를 포함하는 감광성 수지 조성물 및 컬러필터
|
|
WO2015116539A1
(en)
|
2014-01-28 |
2015-08-06 |
Bristol-Myers Squibb Company |
Anti-lag-3 antibodies to treat hematological malignancies
|
|
CN122399016A
(zh)
|
2014-03-15 |
2026-07-17 |
诺华股份有限公司 |
使用嵌合抗原受体治疗癌症
|
|
TWI754319B
(zh)
|
2014-03-19 |
2022-02-01 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
|
MX380176B
(es)
|
2014-04-07 |
2025-03-12 |
Chugai Pharmaceutical Co Ltd |
Molecula ligada a antigeno inmunoactivada.
|
|
CN106459204B
(zh)
|
2014-04-25 |
2021-02-02 |
皮埃尔法布雷医药公司 |
Igf-1r抗体及其作为定位载体用于治疗癌症的用途
|
|
TWI693232B
(zh)
*
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
|
PT3177644T
(pt)
|
2014-08-05 |
2021-01-13 |
MabQuest SA |
Reagentes imunológicos que se ligam a pd-1
|
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
|
JO3663B1
(ar)
*
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
|
PL3209698T5
(pl)
|
2014-10-22 |
2022-04-25 |
Crescendo Biologics Limited |
Mysz transgeniczna
|
|
WO2016073760A1
(en)
|
2014-11-05 |
2016-05-12 |
The Regents Of The University Of California |
Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
|
|
CA2971734C
(en)
|
2014-12-22 |
2025-11-18 |
Pd-1 Acquisition Group, Llc |
Anti-pd-1 antibodies
|
|
DK3298030T5
(en)
|
2015-05-18 |
2024-10-07 |
Pieris Pharmaceuticals Gmbh |
Anti-cancerfusionspolypeptid
|
|
CN105061597B
(zh)
|
2015-06-09 |
2016-04-27 |
北京东方百泰生物科技有限公司 |
一种抗pd-1的单克隆抗体及其获得方法
|
|
EP3328418A1
(en)
*
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
|
PE20231958A1
(es)
*
|
2015-07-30 |
2023-12-06 |
Macrogenics Inc |
Moleculas de union a pd-1 y metodos de uso de las mismas
|
|
CN106397592A
(zh)
|
2015-07-31 |
2017-02-15 |
苏州康宁杰瑞生物科技有限公司 |
针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白
|
|
CN105384825B
(zh)
|
2015-08-11 |
2018-06-01 |
南京传奇生物科技有限公司 |
一种基于单域抗体的双特异性嵌合抗原受体及其应用
|
|
PE20181349A1
(es)
|
2015-10-07 |
2018-08-22 |
Hoffmann La Roche |
Anticuerpos biespecificos con tetravalencia para un receptor de fnt coestimulador
|
|
IL300122A
(en)
*
|
2015-11-18 |
2023-03-01 |
Merck Sharp ַ& Dohme Llc |
Substances that bind to PD1 and/or LAG3
|
|
IL304871A
(en)
|
2016-01-11 |
2023-10-01 |
Inhibrx Inc |
Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses
|
|
JP2019506155A
(ja)
|
2016-01-12 |
2019-03-07 |
クレッシェンド、バイオロジックス、リミテッドＣｒｅｓｃｅｎｄｏ Ｂｉｏｌｏｇｉｃｓ Ｌｉｍｉｔｅｄ |
治療分子
|
|
GB201607968D0
(en)
|
2016-05-06 |
2016-06-22 |
Crescendo Biolog Ltd |
Chimeric antigen receptor
|
|
KR102530742B1
(ko)
|
2016-05-20 |
2023-05-09 |
하푼 테라퓨틱스, 인크. |
단일 도메인 혈청 알부민 결합 단백질
|
|
KR20190014525A
(ko)
|
2016-05-27 |
2019-02-12 |
애브비 바이오테라퓨틱스 인크. |
면역 조절 단백질과 종양 항원을 결합하는 이중특이적 결합 단백질
|
|
WO2018104444A1
(en)
|
2016-12-07 |
2018-06-14 |
Ablynx Nv |
Improved serum albumin binding immunoglobulin single variable domains
|
|
EP3565842A1
(en)
|
2017-01-06 |
2019-11-13 |
Crescendo Biologics Limited |
Single domain antibodies to programmed cell death (pd-1)
|
|
WO2018148223A1
(en)
|
2017-02-09 |
2018-08-16 |
Memorial Sloan Kettering Cancer Center |
Anti-kir3dl1 antibodies
|
|
WO2018224439A1
(en)
|
2017-06-05 |
2018-12-13 |
Numab Innovation Ag |
Novel anti-hsa antibodies
|
|
EP3425763B1
(en)
*
|
2017-07-03 |
2020-11-18 |
France Brevets |
Coupling interface and method of operation
|
|
KR20200037250A
(ko)
*
|
2017-07-06 |
2020-04-08 |
메뤼스 엔.페. |
세포에 의해 발현되는 생물학적 활성을 조절하는 항체
|
|
GB201711068D0
(en)
|
2017-07-10 |
2017-08-23 |
Crescendo Biologics Ltd |
Therapeutic molecules binding PSMA
|
|
EP3470426A1
(en)
|
2017-10-10 |
2019-04-17 |
Numab Therapeutics AG |
Multispecific antibody
|
|
CA3082297A1
(en)
|
2017-11-13 |
2019-05-16 |
Crescendo Biologics Limited |
Molecules that bind to cd137 and psma
|
|
GB201802573D0
(en)
|
2018-02-16 |
2018-04-04 |
Crescendo Biologics Ltd |
Therapeutic molecules that bind to LAG3
|
|
GB201818460D0
(en)
|
2018-11-13 |
2018-12-26 |
Crescendo Biologics Ltd |
Single domain antibodies that bind human serum albumin
|
|
US20220220215A1
(en)
|
2019-05-15 |
2022-07-14 |
Crescendo Biologics Limited |
Binding molecules
|